Nektar Therapeutics
NASDAQ:NKTR
Nektar Therapeutics
Depreciation & Amortization
Nektar Therapeutics
Depreciation & Amortization Peer Comparison
Competitive Depreciation & Amortization Analysis
Latest Figures & CAGR of Competitors
Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Nektar Therapeutics
NASDAQ:NKTR
|
Depreciation & Amortization
$7.1m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-7%
|
|
Johnson & Johnson
NYSE:JNJ
|
Depreciation & Amortization
$7.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
6%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Depreciation & Amortization
$9.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
72%
|
CAGR 10-Years
31%
|
|
Pfizer Inc
NYSE:PFE
|
Depreciation & Amortization
$6.5B
|
CAGR 3-Years
11%
|
CAGR 5-Years
1%
|
CAGR 10-Years
1%
|
|
Merck & Co Inc
NYSE:MRK
|
Depreciation & Amortization
$3.9B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-6%
|
|
Eli Lilly and Co
NYSE:LLY
|
Depreciation & Amortization
$1.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
See Also
What is Nektar Therapeutics's Depreciation & Amortization?
Depreciation & Amortization
7.1m
USD
Based on the financial report for Mar 31, 2024, Nektar Therapeutics's Depreciation & Amortization amounts to 7.1m USD.
What is Nektar Therapeutics's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
-7%
Over the last year, the Depreciation & Amortization growth was -39%. The average annual Depreciation & Amortization growth rates for Nektar Therapeutics have been -19% over the past three years , -9% over the past five years , and -7% over the past ten years .